{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:45:55Z","timestamp":1783154755008,"version":"3.54.6"},"reference-count":31,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.vaccine.2022.03.036","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:12:49Z","timestamp":1648167169000},"page":"2551-2560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines"],"prefix":"10.1016","volume":"40","author":[{"given":"Sira","family":"Nanthapisal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyawee","family":"Puthanakit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peera","family":"Jaru-Ampornpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8995-0990","authenticated-orcid":false,"given":"Rapisa","family":"Nantanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimpayao","family":"Sodsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orawan","family":"Himananto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiratchaya","family":"Sophonphan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pintip","family":"Suchartlikitwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narin","family":"Hiransuthikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pornpimon","family":"Angkasekwinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auchara","family":"Tangsathapornpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattiya","family":"Hirankarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.03.036_b0005","unstructured":"WHO. WHO Coronavirus (COVID-19) Dashboard [Available from: https:\/\/covid19.who.int\/. Accessed date 20 January, 2022."},{"key":"10.1016\/j.vaccine.2022.03.036_b0010","unstructured":"WHO. COVID-19 Weekly Epidemiological Update Edition 68, published 30 November 2021 2021 [Available from: https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---30-november-2021. Accessed date 7 December, 2021."},{"issue":"7","key":"10.1016\/j.vaccine.2022.03.036_b0015","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMc2107799","article-title":"Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants","volume":"385","author":"Edara","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.03.036_b0020","unstructured":"WHO. Interim statement on COVID-19 vaccine booster doses 2021 [updated 10 August 2021. Available from: https:\/\/www.who.int\/news\/item\/10-08-2021-interim-statement-on-covid-19-vaccine-booster-doses. Accessed date 29 August, 2021."},{"issue":"10","key":"10.1016\/j.vaccine.2022.03.036_b0025","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.03.036_b0030","unstructured":"WHO. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19 2021 [Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-background-2021.1. Accessed date 31 July 2021, 2021."},{"key":"10.1016\/j.vaccine.2022.03.036_b0035","doi-asserted-by":"crossref","unstructured":"Jantarabenjakul W, Chantasrisawad N, Puthanakit T, Wacharapluesadee S, Hirankarn N, Ruenjaiman V, et al. Short-term immune response after inactivated SARS-CoV-2 (CoronaVac(R), Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria(R), Oxford-AstraZeneca) vaccinations in health care workers. Asian Pac J Allergy Immunol 2021. 10.12932\/AP-250721-1197","DOI":"10.1101\/2021.08.27.21262721"},{"issue":"10","key":"10.1016\/j.vaccine.2022.03.036_b0040","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S1473-3099(21)00568-5","article-title":"CoronaVac induces lower neutralising activity against variants of concern than natural infection","volume":"21","author":"Vacharathit","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.036_b0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2022.03.036_b0050","article-title":"Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells","author":"Mateus","year":"20219853","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.vaccine.2022.03.036_b0055","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.03.036_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.612747","article-title":"Optimize Prime\/Boost Vaccine Strategies: trained Immunity as a New Player in the Game","volume":"12","author":"Palgen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.03.036_b0065","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.03.036_b0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","author":"Barros-Martins","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.vaccine.2022.03.036_b0075","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.vaccine.2021.11.083","article-title":"Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults","volume":"40","author":"Yorsaeng","year":"2022","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.03.036_b0080","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/vaccines9121375","article-title":"Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population","volume":"9","author":"Intapiboon","year":"2021","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2022.03.036_b0085","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.03.036_b0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","author":"Feng","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.vaccine.2022.03.036_b0095","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2022.03.036_b0100","unstructured":"U.S. Department of Health and Human Services F, CBER. Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials September 2007 [Available from: https:\/\/www.fda.gov\/media\/73679\/download. Accessed date 30 November, 2021."},{"key":"10.1016\/j.vaccine.2022.03.036_b0105","unstructured":"WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations, WHO Technical Report Series 1004, Annex 9, 2017 2017 [Available from: https:\/\/www.who.int\/publications\/m\/item\/WHO-TRS-1004-web-annex-9. Accessed date 12 December, 2021."},{"key":"10.1016\/j.vaccine.2022.03.036_b0110","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2022.03.036_b0115","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5114\/ceji.2018.77390","article-title":"Immunological memory cells","volume":"43","author":"Ratajczak","year":"2018","journal-title":"Cent Eur J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.03.036_b0120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/voxs.12644","article-title":"Correlation of sample-to-cut-off ratio of anti-SARS-CoV-2 IgG antibody chemiluminescent assay with neutralization activity: a prospective multi-centric study in India","volume":"16","author":"Tiwari","year":"2021","journal-title":"ISBT Science Series"},{"key":"10.1016\/j.vaccine.2022.03.036_b0125","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2022.03.036_b0130","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/14760584.2021.1971522","article-title":"To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination","volume":"20","author":"Chiu","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.03.036_b0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/d41586-021-01497-8","article-title":"WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic","volume":"594","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.03.036_b0140","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2022.03.036_b0145","unstructured":"Ritchie H, Mathieu E, Rod\u00e9s-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19) 2020 [Available from: https:\/\/ourworldindata.org\/covid-vaccinations. Accessed date 24 January, 2022."},{"issue":"12","key":"10.1016\/j.vaccine.2022.03.036_b0150","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.vaccine.2022.02.019","article-title":"Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19\/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: a randomized controlled trial","volume":"40","author":"Tawinprai","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.03.036_b0155","first-page":"1","article-title":"Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India","author":"Du","year":"2022","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2200336X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2200336X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:12:13Z","timestamp":1759403533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2200336X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":31,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0264410X2200336X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.036","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.15.22270974","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}